Keywords: Pfizer, Axitinib, Kidney cancer, Renal cell carcinoma, USA, FDA

US FDA accepts Pfizer NDA for kidney cancer drug axitinib

Article | 29 June 2011

Print This

The US Food and Drug Administration has accepted global drugs behemoth Pfizer’s (NYSE: PFE) filing for standard review ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in